Lanxess Q4 2011 income fell to €5m, down 80% from €26m in 2010. The company attributed this to a €20m charge for the realignment of the pharma business of the Saltigo business unit.
Lanxess
Monday 26 March 2012
Saltigo realignment hits Lanxess
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment